Loading...
XKRX
290650
Market cap1.05bUSD
Jul 10, Last price  
72,700.00KRW
1D
4.15%
1Q
4.30%
IPO
695.99%
Name

L&C Bio Co Ltd

Chart & Performance

D1W1MN
XKRX:290650 chart
P/E
P/S
19.29
EPS
Div Yield, %
0.07%
Shrs. gr., 5y
2.37%
Rev. gr., 5y
20.99%
Revenues
85.48b
+18.56%
8,999,068,63011,821,737,96017,900,842,82021,240,893,56029,151,665,00032,972,771,00045,677,014,00052,572,492,00068,869,546,00072,093,323,00085,476,415,000
Net income
-138.17b
L
1,202,060,7501,981,143,8903,753,072,9505,207,676,9107,250,030,00010,813,094,00013,814,433,0004,544,175,00048,361,015,000141,064,261,000-138,174,717,000
CFO
12.56b
P
-1,327,717,960-185,353,5703,818,116,8103,845,774,8206,430,855,6207,419,054,67010,906,636,000-6,075,796,000-12,132,875,000-8,566,587,00012,564,733,000
Dividend
Dec 29, 202550 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Specializing in regenerative tissue medicine, L&C BIO Co., Ltd. operates as a dedicated research and development enterprise. The company's diverse product range encompasses human tissue products, various medical devices, and a selection of cosmetic solutions. Established in 2011, this firm is headquartered in Seongnam, South Korea.
IPO date
Nov 01, 2018
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT